Period,symbol,NAV,sharesOutstanding,researchDevelopment,effectOfAccountingCharges,incomeBeforeTax,minorityInterest,netIncome,sellingGeneralAdministrative,grossProfit,ebit,operatingIncome,otherOperatingExpenses,interestExpense,extraordinaryItems,nonRecurring,otherItems,incomeTaxExpense,totalRevenue,totalOperatingExpenses,costOfRevenue,totalOtherIncomeExpenseNet,discontinuedOperations,netIncomeFromContinuingOps,netIncomeApplicableToCommonShares,capitalSurplus,totalLiab,totalStockholderEquity,otherCurrentLiab,totalAssets,commonStock,retainedEarnings,otherLiab,treasuryStock,otherAssets,cash,totalCurrentLiabilities,otherStockholderEquity,propertyPlantEquipment,totalCurrentAssets,longTermInvestments,shortTermInvestments,netReceivables,accountsPayable,investments,changeToLiabilities,totalCashflowsFromInvestingActivities,netBorrowings,totalCashFromFinancingActivities,changeToOperatingActivities,issuanceOfStock,changeInCash,totalCashFromOperatingActivities,depreciation,changeToAccountReceivables,otherCashflowsFromFinancingActivities,changeToNetincome,capitalExpenditures,repurchaseOfStock,WC,language,region,quoteType,triggerable,quoteSourceName,currency,market,regularMarketPrice,regularMarketTime,regularMarketChange,regularMarketOpen,regularMarketDayHigh,regularMarketDayLow,regularMarketVolume,shortName,exchange,marketState,twoHundredDayAverageChangePercent,exchangeDataDelayedBy,esgPopulated,tradeable,regularMarketChangePercent,regularMarketDayRange,regularMarketPreviousClose,bid,ask,bidSize,askSize,messageBoardId,fullExchangeName,longName,financialCurrency,averageDailyVolume3Month,averageDailyVolume10Day,fiftyTwoWeekLowChange,fiftyTwoWeekLowChangePercent,fiftyTwoWeekRange,fiftyTwoWeekHighChange,fiftyTwoWeekHighChangePercent,fiftyTwoWeekLow,fiftyTwoWeekHigh,earningsTimestamp,earningsTimestampStart,earningsTimestampEnd,priceHint,epsCurrentYear,priceEpsCurrentYear,fiftyDayAverage,fiftyDayAverageChange,fiftyDayAverageChangePercent,twoHundredDayAverage,twoHundredDayAverageChange,marketCap,sourceInterval,exchangeTimezoneName,exchangeTimezoneShortName,gmtOffSetMilliseconds,Beta (5Y Monthly),52-Week Change 3,S&P500 52-Week Change 3,52 Week High 3,52 Week Low 3,50-Day Moving Average 3,200-Day Moving Average 3,Avg Vol (3 month) 3,Avg Vol (10 day) 3,Shares Outstanding 5,Implied Shares Outstanding 6,Float,% Held by Insiders 1,% Held by Institutions 1,"Shares Short (May 27, 2021) 4","Short Ratio (May 27, 2021) 4","Short % of Float (May 27, 2021) 4","Short % of Shares Outstanding (May 27, 2021) 4","Shares Short (prior month Apr 29, 2021) 4",Forward Annual Dividend Rate 4,Forward Annual Dividend Yield 4,Trailing Annual Dividend Rate 3,Trailing Annual Dividend Yield 3,5 Year Average Dividend Yield 4,Payout Ratio 4,Dividend Date 3,Ex-Dividend Date 4,Last Split Factor 2,Last Split Date 3,Fiscal Year Ends,Most Recent Quarter (mrq),Profit Margin,Operating Margin (ttm),Return on Assets (ttm),Return on Equity (ttm),Revenue (ttm),Revenue Per Share (ttm),Quarterly Revenue Growth (yoy),Gross Profit (ttm),EBITDA,Net Income Avi to Common (ttm),Diluted EPS (ttm),Quarterly Earnings Growth (yoy),Total Cash (mrq),Total Cash Per Share (mrq),Total Debt (mrq),Total Debt/Equity (mrq),Current Ratio (mrq),Book Value Per Share (mrq),Operating Cash Flow (ttm),Levered Free Cash Flow (ttm),index,zip,sector,fullTimeEmployees,longBusinessSummary,city,phone,state,compensationAsOfEpochDate,country,website,maxAge,address1,industry,address2
t0,DBTX,180266000.0,24901900,6020000,,-10870000,,-10870000,4883000,0,-10903000,-10903000,,,,,,0,0,10903000,0,33000,,-10870000,-13179000,353821000.0,26820000.0,180266000.0,10356000.0,207086000.0,25000.0,-173559000.0,11629000.0,-21000.0,1378000.0,52239000.0,15191000.0,-21000.0,5975000.0,190734000.0,8999000.0,129839000.0,4237000.0,1000000.0,-112378000.0,-1131000.0,-112443000.0,-46000.0,153148000.0,-2466000.0,128257000.0,24399000.0,-16306000.0,427000.0,-3000000.0,-2463000.0,734000.0,-65000.0,,175543000.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,USD,us_market,7.9001,1630503127,-0.16989946,8.09,8.09,7.9001,531,"Decibel Therapeutics, Inc.",NMS,REGULAR,-0.2120512,0,False,False,-2.105322,7.9001 - 8.09,8.07,7.5,8.1,8,10,finmb_314238373,NasdaqGS,"Decibel Therapeutics, Inc.",USD,101348,45300,1.7201004,0.2783334,6.18 - 24.39,-16.489899,-0.6760926,6.18,24.39,1620936000,1620936000,1620936000,2,-2.09,-3.7799525,7.258611,0.641489,0.088376276,10.026159,-2.126059,197948064,15,America/New_York,EDT,-14400000,,,,24.39,6.18,7.26,10.03,101.35k,45.3k,24.9M,,11.13M,9.28%,73.75%,607.64k,6.46,3.90%,2.44%,510.51k,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",0.00%,0.00%,,,,,,,-36.72M,8.18M,,,182.08M,7.32,197k,0.11,12.56,,-37.06M,,Value,02215,Healthcare,40,"Decibel Therapeutics, Inc., a clinical-stage biotechnology company, engages in discovering and developing transformative treatments for hearing and balance disorders. Its product candidates and programs focuses on three areas, such as Gene Therapies for Congenital, Monogenic Hearing Loss designed to restore functional cells within the cochlea to address hearing disorders caused by single gene mutations; Gene Therapies for Hair Cell Regeneration designed to replace lost hair cells within the inner ear to address acquired hearing loss and balance disorders; and Otoprotection Therapeutic in clinical development to prevent hearing loss in cancer patients undergoing chemotherapy with cisplatin. The company's lead gene therapy product candidate is DB-OTO to provide hearing to individuals born with profound hearing loss due to mutation of the otoferlin gene. It is also developing DB-ATO, a gene therapy program designed to restore balance in patients with bilateral vestibulopathy by regenerating lost hair cells within the inner ear; and DB-020 for the prevention of cisplatin-induced hearing loss, which is in Phase 1b clinical trial. Decibel Therapeutics, Inc. has a strategic collaboration with Regeneron Pharmaceuticals, Inc. to develop gene therapies for monogenic forms of congenital hearing loss. The company was formerly known as Hearing Inc. and changed its name to Decibel Therapeutics, Inc. in April 2014. Decibel Therapeutics, Inc. was incorporated in 2013 and is headquartered in Boston, Massachusetts.",Boston,617 370 8701,MA,1609372800,United States,http://www.decibeltx.com,86400,1325 Boylston Street,Biotechnology,Suite 500
t-1,DBTX,-54781000.0,24901900,7896000,,-12884000,,-12884000,5111000,0,-13007000,-13007000,,-48000.0,,,,0,0,13007000,0,123000,,-12884000,41805000,107908000.0,28975000.0,-54781000.0,11578000.0,67285000.0,1000.0,-162689000.0,9401000.0,-1000.0,3120000.0,27742000.0,19374000.0,-1000.0,6337000.0,57828000.0,,26568000.0,1237000.0,2131000.0,-26582000.0,937000.0,-26694000.0,-45000.0,54387000.0,5472000.0,70000.0,22544000.0,-5149000.0,345000.0,-1237000.0,-426000.0,2218000.0,-112000.0,-12000.0,38454000.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,USD,us_market,7.9001,1630503127,-0.16989946,8.09,8.09,7.9001,531,"Decibel Therapeutics, Inc.",NMS,REGULAR,-0.2120512,0,False,False,-2.105322,7.9001 - 8.09,8.07,7.5,8.1,8,10,finmb_314238373,NasdaqGS,"Decibel Therapeutics, Inc.",USD,101348,45300,1.7201004,0.2783334,6.18 - 24.39,-16.489899,-0.6760926,6.18,24.39,1620936000,1620936000,1620936000,2,-2.09,-3.7799525,7.258611,0.641489,0.088376276,10.026159,-2.126059,197948064,15,America/New_York,EDT,-14400000,,,,24.39,6.18,7.26,10.03,101.35k,45.3k,24.9M,,11.13M,9.28%,73.75%,607.64k,6.46,3.90%,2.44%,510.51k,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",0.00%,0.00%,,,,,,,-36.72M,8.18M,,,182.08M,7.32,197k,0.11,12.56,,-37.06M,,Value,02215,Healthcare,40,"Decibel Therapeutics, Inc., a clinical-stage biotechnology company, engages in discovering and developing transformative treatments for hearing and balance disorders. Its product candidates and programs focuses on three areas, such as Gene Therapies for Congenital, Monogenic Hearing Loss designed to restore functional cells within the cochlea to address hearing disorders caused by single gene mutations; Gene Therapies for Hair Cell Regeneration designed to replace lost hair cells within the inner ear to address acquired hearing loss and balance disorders; and Otoprotection Therapeutic in clinical development to prevent hearing loss in cancer patients undergoing chemotherapy with cisplatin. The company's lead gene therapy product candidate is DB-OTO to provide hearing to individuals born with profound hearing loss due to mutation of the otoferlin gene. It is also developing DB-ATO, a gene therapy program designed to restore balance in patients with bilateral vestibulopathy by regenerating lost hair cells within the inner ear; and DB-020 for the prevention of cisplatin-induced hearing loss, which is in Phase 1b clinical trial. Decibel Therapeutics, Inc. has a strategic collaboration with Regeneron Pharmaceuticals, Inc. to develop gene therapies for monogenic forms of congenital hearing loss. The company was formerly known as Hearing Inc. and changed its name to Decibel Therapeutics, Inc. in April 2014. Decibel Therapeutics, Inc. was incorporated in 2013 and is headquartered in Boston, Massachusetts.",Boston,617 370 8701,MA,1609372800,United States,http://www.decibeltx.com,86400,1325 Boylston Street,Biotechnology,Suite 500
t-2,DBTX,-121796000.0,24901900,5217000,,-11535000,,-11535000,3478000,0,-8695000,-8695000,,-48000.0,,,,0,0,8695000,0,-2840000,,-11535000,-14284000,,,-121796000.0,,,,,,,,,,,,,,,,,11750000.0,-57000.0,11694000.0,-45000.0,54387000.0,-982000.0,70000.0,-212000.0,-11906000.0,487000.0,-1237000.0,-426000.0,181000.0,-56000.0,-12000.0,,en-US,US,EQUITY,True,Nasdaq Real Time Price,USD,us_market,7.9001,1630503127,-0.16989946,8.09,8.09,7.9001,531,"Decibel Therapeutics, Inc.",NMS,REGULAR,-0.2120512,0,False,False,-2.105322,7.9001 - 8.09,8.07,7.5,8.1,8,10,finmb_314238373,NasdaqGS,"Decibel Therapeutics, Inc.",USD,101348,45300,1.7201004,0.2783334,6.18 - 24.39,-16.489899,-0.6760926,6.18,24.39,1620936000,1620936000,1620936000,2,-2.09,-3.7799525,7.258611,0.641489,0.088376276,10.026159,-2.126059,197948064,15,America/New_York,EDT,-14400000,,,,24.39,6.18,7.26,10.03,101.35k,45.3k,24.9M,,11.13M,9.28%,73.75%,607.64k,6.46,3.90%,2.44%,510.51k,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",0.00%,0.00%,,,,,,,-36.72M,8.18M,,,182.08M,7.32,197k,0.11,12.56,,-37.06M,,Value,02215,Healthcare,40,"Decibel Therapeutics, Inc., a clinical-stage biotechnology company, engages in discovering and developing transformative treatments for hearing and balance disorders. Its product candidates and programs focuses on three areas, such as Gene Therapies for Congenital, Monogenic Hearing Loss designed to restore functional cells within the cochlea to address hearing disorders caused by single gene mutations; Gene Therapies for Hair Cell Regeneration designed to replace lost hair cells within the inner ear to address acquired hearing loss and balance disorders; and Otoprotection Therapeutic in clinical development to prevent hearing loss in cancer patients undergoing chemotherapy with cisplatin. The company's lead gene therapy product candidate is DB-OTO to provide hearing to individuals born with profound hearing loss due to mutation of the otoferlin gene. It is also developing DB-ATO, a gene therapy program designed to restore balance in patients with bilateral vestibulopathy by regenerating lost hair cells within the inner ear; and DB-020 for the prevention of cisplatin-induced hearing loss, which is in Phase 1b clinical trial. Decibel Therapeutics, Inc. has a strategic collaboration with Regeneron Pharmaceuticals, Inc. to develop gene therapies for monogenic forms of congenital hearing loss. The company was formerly known as Hearing Inc. and changed its name to Decibel Therapeutics, Inc. in April 2014. Decibel Therapeutics, Inc. was incorporated in 2013 and is headquartered in Boston, Massachusetts.",Boston,617 370 8701,MA,1609372800,United States,http://www.decibeltx.com,86400,1325 Boylston Street,Biotechnology,Suite 500
t-3,DBTX,-121796000.0,24901900,3174000,,-6219000,,-6219000,3262000,0,-6436000,-6436000,,-48000.0,,,,0,0,6436000,0,217000,,-6219000,-8998000,1546000.0,26987000.0,-121796000.0,4190000.0,42835000.0,,-123352000.0,17535000.0,10000.0,1439000.0,18600000.0,9452000.0,10000.0,7825000.0,33571000.0,,13714000.0,,1008000.0,13233000.0,-299000.0,13155000.0,-45000.0,-3000.0,-4864000.0,70000.0,2555000.0,-10597000.0,554000.0,-1237000.0,-426000.0,231000.0,-78000.0,-3000.0,24119000.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,USD,us_market,7.9001,1630503127,-0.16989946,8.09,8.09,7.9001,531,"Decibel Therapeutics, Inc.",NMS,REGULAR,-0.2120512,0,False,False,-2.105322,7.9001 - 8.09,8.07,7.5,8.1,8,10,finmb_314238373,NasdaqGS,"Decibel Therapeutics, Inc.",USD,101348,45300,1.7201004,0.2783334,6.18 - 24.39,-16.489899,-0.6760926,6.18,24.39,1620936000,1620936000,1620936000,2,-2.09,-3.7799525,7.258611,0.641489,0.088376276,10.026159,-2.126059,197948064,15,America/New_York,EDT,-14400000,,,,24.39,6.18,7.26,10.03,101.35k,45.3k,24.9M,,11.13M,9.28%,73.75%,607.64k,6.46,3.90%,2.44%,510.51k,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",0.00%,0.00%,,,,,,,-36.72M,8.18M,,,182.08M,7.32,197k,0.11,12.56,,-37.06M,,Value,02215,Healthcare,40,"Decibel Therapeutics, Inc., a clinical-stage biotechnology company, engages in discovering and developing transformative treatments for hearing and balance disorders. Its product candidates and programs focuses on three areas, such as Gene Therapies for Congenital, Monogenic Hearing Loss designed to restore functional cells within the cochlea to address hearing disorders caused by single gene mutations; Gene Therapies for Hair Cell Regeneration designed to replace lost hair cells within the inner ear to address acquired hearing loss and balance disorders; and Otoprotection Therapeutic in clinical development to prevent hearing loss in cancer patients undergoing chemotherapy with cisplatin. The company's lead gene therapy product candidate is DB-OTO to provide hearing to individuals born with profound hearing loss due to mutation of the otoferlin gene. It is also developing DB-ATO, a gene therapy program designed to restore balance in patients with bilateral vestibulopathy by regenerating lost hair cells within the inner ear; and DB-020 for the prevention of cisplatin-induced hearing loss, which is in Phase 1b clinical trial. Decibel Therapeutics, Inc. has a strategic collaboration with Regeneron Pharmaceuticals, Inc. to develop gene therapies for monogenic forms of congenital hearing loss. The company was formerly known as Hearing Inc. and changed its name to Decibel Therapeutics, Inc. in April 2014. Decibel Therapeutics, Inc. was incorporated in 2013 and is headquartered in Boston, Massachusetts.",Boston,617 370 8701,MA,1609372800,United States,http://www.decibeltx.com,86400,1325 Boylston Street,Biotechnology,Suite 500
